Clinical trial
A Phase 1 Safety and Efficacy Study of STIL101 for Injection in Locally Advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Renal Cell Carcinoma, Cervical Cancer, and Melanoma
NCT06626256 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Safety and Efficacy Study of STIL101 for Injection in Locally Advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Renal Cell Carcinoma, Cervical Cancer, and Melanoma
- Lead sponsor
- City of Hope Medical Center
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- December 5, 2025
- Completion date
- October 30, 2027
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced cervical carcinoma, locally advanced colorectal carcinoma, locally advanced malignant solid neoplasm, locally advanced melanoma, locally advanced pancreatic ductal adenocarcinoma, locally advanced renal cell carcinoma, metastatic cervical carcinoma, metastatic colorectal carcinoma, metastatic malignant solid neoplasm, metastatic melanoma, metastatic pancreatic ductal adenocarcinoma, metastatic renal cell carcinoma, stage ii pancreatic cancer ajcc v8, stage iii cervical cancer ajcc v8, stage iii colorectal cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iii renal cell cancer ajcc v8, stage iv cervical cancer ajcc v8, stage iv colorectal cancer ajcc v8, stage iv pancreatic cancer ajcc v8, stage iv renal cell cancer ajcc v8, unresectable cervical carcinoma, unresectable colorectal carcinoma, unresectable malignant solid neoplasm, unresectable melanoma, unresectable pancreatic ductal adenocarcinoma, unresectable renal cell carcinoma